BRIEF

on GUERBET (EPA:GBT)

Hugues Lecat Appointed Chairman of the Board of Directors at Guerbet

Villepinte, 24 May 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, has announced the appointment of Hugues Lecat as Chairman of the Board of Directors, following the previously announced timetable.

During the Annual General Meeting held at the registered office, the Board of Directors unanimously appointed Lecat on the recommendation of the Appointments and Remuneration Committee. This dual appointment ends his role as “censeur” since 20 March 2024. Didier Izabel will continue as director and Chairman of the Audit Committee until 2026.

Lecat expressed gratitude towards the shareholders and Board members, including Izabel. He highlighted the Group’s strategic acceleration in MRI and innovative AI solutions as key focus areas.

Lecat, a NEOMA business school and INSEAD graduate, has significant experience in the pharmaceutical sector, holding various senior roles, including CEO positions at Théraplix, Sanofi-Aventis OTC, and Ethypharm.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all GUERBET news